- IBIO-201 Demonstrates Ability to Elicit anti-SARS-CoV-2 Immune Response in Preclinical Studies -
August 10, 2020 07:15 ET | Source: iBio, Inc.
NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biotechnology corporation and biologics contract manufacturing organization, today provided an update on one...
